FSRH Clinical Guideline: Intrauterine contraception (March 2023, Amended July 2023)

The guideline provides evidence-based recommendations and good practice points to enable clinicians to support individuals to make informed decisions about choosing and using IUC. It includes information on assessing suitability of IUC use for contraception, the risks and benefits of IUC and guidance for IUC procedures, complications and follow-up. Published March 2023.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

The digital version can be accessed from the BMJ SRH website: FSRH Guideline (March 2023) Intrauterine contraception BMJ Sexual & Reproductive Health 2023;49:1-142.